• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CMB 0.00% 0.4¢

CAMBIUM BIO LIMITED - News & Media

Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage... Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No News & Media currently available.

(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $4.772M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
7 1267251 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.6¢ 746300 6
Last trade - 16.12pm 03/07/2024 (20 minute delay) ?
CMB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.